Literature DB >> 21910217

X-linked VACTERL with hydrocephalus syndrome: further delineation of the phenotype caused by FANCB mutations.

Joanna McCauley1, Navta Masand, Ruth McGowan, Sulekha Rajagopalan, Alasdair Hunter, Jacques L Michaud, Kate Gibson, Jeremy Robertson, Fiona Vaz, Stephen Abbs, Simon T Holden.   

Abstract

X-linked VACTERL-hydrocephalus syndrome (X-linked VACTERL-H) is a rare disorder caused by mutations in the gene FANCB which underlies Fanconi Anemia (FA) complementation group B. Cells from affected males have increased chromosome breakage on exposure to DNA cross-linking agents. Only five FANCB mutations found in six affected males, including an affected uncle and nephew, have been reported. We have identified FANCB mutations in a further four affected families. The VACTERL-H phenotype segregates as an X-linked recessive trait in three of these. Each mutation is predicted to truncate the FANCB open reading frame and results in highly skewed X-inactivation in unaffected carrier females. Phenotypic data were available on six affected males. Comparison of the clinical findings in our patients with published clinical data (total 12 patients) shows that ventriculomegaly, bilateral absent thumbs and radii, vertebral defects, renal agenesis, and growth retardation are the major phenotypic signs in affected males. Less frequent are brain, pituitary, ear and eye malformations, gastrointestinal atresias (esophageal, duodenal and anal), tracheoesophageal fistula, lung segmentation defects, and small genitalia. Three of six of our patients survived the perinatal period. One boy lived up to 2 years 10 months but developed aplastic anemia and died of renal failure. These data show that loss-of-function FANCB mutations result in a recognizable, multiple malformation phenotype in hemizygous males for which we propose clinical criteria to aid diagnosis.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21910217     DOI: 10.1002/ajmg.a.33913

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  15 in total

1.  Considering the Embryopathogenesis of VACTERL Association.

Authors:  R E Stevenson; A G W Hunter
Journal:  Mol Syndromol       Date:  2013-02

Review 2.  An approach to the identification of anomalies and etiologies in neonates with identified or suspected VACTERL (vertebral defects, anal atresia, tracheo-esophageal fistula with esophageal atresia, cardiac anomalies, renal anomalies, and limb anomalies) association.

Authors:  Benjamin D Solomon; Linda A Baker; Kelly A Bear; Bridget K Cunningham; Philip F Giampietro; Colleen Hadigan; Donald W Hadley; Steven Harrison; Marc A Levitt; Nickie Niforatos; Scott M Paul; Cathleen Raggio; Heiko Reutter; Nicole Warren-Mora
Journal:  J Pediatr       Date:  2013-12-12       Impact factor: 4.406

3.  Concomitant inactivation of foxo3a and fancc or fancd2 reveals a two-tier protection from oxidative stress-induced hydrocephalus.

Authors:  Xiaoli Li; Liang Li; Jie Li; Jared Sipple; Jonathan Schick; Parinda A Mehta; Stella M Davies; Biplab Dasgupta; Ronald R Waclaw; Qishen Pang
Journal:  Antioxid Redox Signal       Date:  2014-03-12       Impact factor: 8.401

Review 4.  Infantile hydrocephalus: a review of epidemiology, classification and causes.

Authors:  Hannah M Tully; William B Dobyns
Journal:  Eur J Med Genet       Date:  2014-06-13       Impact factor: 2.708

5.  Beyond Gómez-López-Hernández syndrome: recurring phenotypic themes in rhombencephalosynapsis.

Authors:  Hannah M Tully; Jennifer C Dempsey; Gisele E Ishak; Margaret P Adam; Cynthia J R Curry; Pedro Sanchez-Lara; Alasdair Hunter; Karen W Gripp; Judith Allanson; Christopher Cunniff; Ian Glass; Kathleen J Millen; Daniel Doherty; William B Dobyns
Journal:  Am J Med Genet A       Date:  2012-09-10       Impact factor: 2.802

6.  Association of clinical severity with FANCB variant type in Fanconi anemia.

Authors:  Moonjung Jung; Ramanagouda Ramanagoudr-Bhojappa; Sylvie van Twest; Rasim Ozgur Rosti; Vincent Murphy; Winnie Tan; Frank X Donovan; Francis P Lach; Danielle C Kimble; Caroline S Jiang; Roger Vaughan; Parinda A Mehta; Filomena Pierri; Carlo Dufour; Arleen D Auerbach; Andrew J Deans; Agata Smogorzewska; Settara C Chandrasekharappa
Journal:  Blood       Date:  2020-04-30       Impact factor: 25.476

7.  AluY-mediated germline deletion, duplication and somatic stem cell reversion in UBE2T defines a new subtype of Fanconi anemia.

Authors:  Elizabeth L Virts; Anna Jankowska; Craig Mackay; Marcel F Glaas; Constanze Wiek; Stephanie L Kelich; Nadine Lottmann; Felicia M Kennedy; Christophe Marchal; Erik Lehnert; Rüdiger E Scharf; Carlo Dufour; Marina Lanciotti; Piero Farruggia; Alessandra Santoro; Süreyya Savasan; Kathrin Scheckenbach; Jörg Schipper; Martin Wagenmann; Todd Lewis; Michael Leffak; Janice L Farlow; Tatiana M Foroud; Ellen Honisch; Dieter Niederacher; Sujata C Chakraborty; Gail H Vance; Dmitry Pruss; Kirsten M Timms; Jerry S Lanchbury; Arno F Alpi; Helmut Hanenberg
Journal:  Hum Mol Genet       Date:  2015-06-17       Impact factor: 6.150

8.  Coinheritance of COL4A5 and MYO1E mutations accentuate the severity of kidney disease.

Authors:  Rachel Lennon; Helen M Stuart; Agnieszka Bierzynska; Michael J Randles; Bronwyn Kerr; Katherine A Hillman; Gauri Batra; Joanna Campbell; Helen Storey; Frances A Flinter; Ania Koziell; Gavin I Welsh; Moin A Saleem; Nicholas J A Webb; Adrian S Woolf
Journal:  Pediatr Nephrol       Date:  2015-03-05       Impact factor: 3.714

9.  Fancb deficiency impairs hematopoietic stem cell function.

Authors:  Wei Du; Surya Amarachintha; Ozlem Erden; Andrew Wilson; Amom Ruhikanta Meetei; Paul R Andreassen; Satoshi H Namekawa; Qishen Pang
Journal:  Sci Rep       Date:  2015-12-11       Impact factor: 4.379

10.  FANCM-associated proteins MHF1 and MHF2, but not the other Fanconi anemia factors, limit meiotic crossovers.

Authors:  Chloe Girard; Wayne Crismani; Nicole Froger; Julien Mazel; Afef Lemhemdi; Christine Horlow; Raphael Mercier
Journal:  Nucleic Acids Res       Date:  2014-07-18       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.